Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
Retrieved on:
星期日, 十一月 26, 2023
Research, Medical Devices, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Rubella, Eye, Adolescence, Fever Dream, School, Safety, Ageing, University, Discipline, Risk, Clinical trial, Vaccination, Bill, Adolescent health, Measles, Refrigeration, Vaccine-preventable diseases, Sunshine Coast, Death, Vaccine, PATH, COVID-19, Phase, Public health, University of Sydney, University of Otago, Skin, Sunshine Coast Region, Transport, Pharmaceutical industry, The Gambia, Child
The study, completed by the University of the Sunshine Coast, in Queensland, Australia, involved the delivery of a measles and rubella (MR) vaccine using the Vaxxas high-density microarray patch (HD-MAP) technology.
Key Points:
- The study, completed by the University of the Sunshine Coast, in Queensland, Australia, involved the delivery of a measles and rubella (MR) vaccine using the Vaxxas high-density microarray patch (HD-MAP) technology.
- Study participants receiving the MR vaccine delivered by HD-MAP, showed a significant increase in neutralizing antibodies compared to placebo and a comparable response to the same comparator vaccine delivered with needle and syringe.
- “We are incredibly pleased with the results of this groundbreaking clinical trial,” David Hoey, Vaxxas Chief Executive Officer, said.
- This planned Phase I/II MR clinical program will be supported in part by an additional grant from the Bill & Melinda Gates Foundation.